Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Marvel obtains Alberta funding for MB-204 phase I

By The Northwire Desk — AI Analysis Mar 30, 2026 · 16:59 MRVL · 0.16 Marvel Biosciences Corp
MRVL · Price

Executive Summary

  • Marvel Biosciences Corp. secured $600,000 in non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support Phase I clinical testing of its lead compound, MB-204.
  • The funding provides third-party validation of the scientific and commercial potential of MB-204, a novel treatment for autism spectrum disorders (ASD) and related conditions.
  • The company also recently received a grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the development of a pediatric-friendly, liquid-based formulation of MB-204.

Key Details

  • Funding Amount: $600,000 CAD.
  • Funding Source: Alberta Innovates CarE (AICE) market access program.
  • Purpose of Funds: To support the overall cost of the Phase I clinical trial of MB-204 and advance the program into human trials.
  • Validation: The AICE program is described as highly competitive and subject to rigorous peer review, serving as third-party validation of MB-204's potential.
  • Additional Grant: Received a separate grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
  • NRC IRAP Purpose: Development of a novel, small volume, liquid-based formulation of MB-204 designed to be pediatric-friendly and improve patient compliance for individuals with difficulty swallowing.
  • Target Indication: Autism spectrum disorders (ASD) and related conditions, specifically addressing sociobehavioural symptoms.
  • Mechanism of Action: MB-204 is a novel fluorinated derivative of Istradefylline (an approved Parkinson's drug) and is an adenosine A2A receptor blocker.
  • Other Potential Indications: Depression, Alzheimer's disease, Rett syndrome, and Fragile X syndrome.
  • Company Status: Transitioning from preclinical innovation to clinical-stage execution.

Notable Quotes

  • "On behalf of Marvel Biosciences, we are very grateful to Alberta Innovates for recognizing the importance and potential of MB-204 as a novel approach to treating autism spectrum disorders (ASD) and related conditions... This competitive, peer-reviewed funding reinforces growing confidence around MB-204, and its potential to address sociobehavioural symptoms through a differentiated mechanism." — Rod Matheson, Chief Executive Officer
Read the original news release →

More from Marvel Biosciences Corp

Jun 08, 2026 · 07:00

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

M&A / Property Apr 23, 2026 · 07:30

Marvel Biosciences Secures Funding and Patent Protection for Phase 1 Neurodevelopmental Candidate MB-204

Other Apr 17, 2026 · 16:30

Marvel Biosciences Closes Financing to Fuel Phase I Transition Amidst Patent Wins

Financings Apr 16, 2026 · 07:00

Marvel Biosciences Advances MB-204 Formulation Ahead of Phase I, But Data Integrity Concerns Linger

Other Apr 13, 2026 · 17:31

Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering

Financings Apr 08, 2026 · 16:31

Small convertible debenture adds cash but raises dilution risk amid mounting debt

Financings